Aurora Spine (ASG) AI Stock Analysis

• Market Cap: C$23.03M
• Dividend Yield: N/A
• Average Volume (3M): 26.17K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.55
• Revenue Growth: 17.61%
• EPS Growth: -19.19%
• Country: CA
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 78,054,950
• 10 Day Avg. Volume: 22,006
• 30 Day Avg. Volume: 26,170
• PEG Ratio: 0.46
• Price to Book (P/B): 4.78
• Price to Sales (P/S): 1.20
• P/FCF Ratio: 78.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: C$0.50 ▲(72.41% Upside)

Aurora Spine's overall stock score is primarily influenced by its mixed financial performance and challenging valuation. The company shows some revenue growth but struggles with profitability and cash flow generation. Technical analysis indicates a stable short-term trend, but the negative P/E ratio and lack of dividend yield weigh on its valuation.

Aurora Spine Business Overview & Revenue Model

Company Description

Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada. The company offers interspinous process lumbar fusion devices, such as the ZIP, ZIP ULTRA, ZIP LP, and ZIP-51 for patients suffering from degenerative disc diseases; and Ti-Coated polyether ether ketone interbody cages, which provide spacing and stability between the vertebrae while bone grows to complete the fusion process. It also provides sterile-packed titanium plasma spray coated spinal infusion implants for bone growth, as well as interbody products, such as EOS, VOX, Echo, Echo SD, and EchoXL for the lumbar section of the spine, and discovery for cervical procedures. In addition, the company provides SOLO, an anterior lumbar interbody fusion 3D printed stand-alone fusion device, which is an integrated plate and spacer system that helps to preserve the natural anatomic profile while providing spinal column support and stability; and SiLo, a posterior fusion device for the sacroiliac joint. Further, it offers DEXA-C, a cervical interbody system, which is a porous 3D-printed intervertebral body fusion device that incorporates low-, mid-, or high-density lattice pattern options to support the matching of patients' bone quality. Aurora Spine Corporation was incorporated in 2013 and is headquartered in Toronto, Canada.

How the Company Makes Money

Aurora Spine generates revenue through the sale of its spinal implant products and surgical instruments to hospitals, surgical centers, and orthopedic practices. The company's revenue model is primarily based on direct sales of its products, which are used in various spinal surgeries. Key revenue streams include the sale of spinal fusion devices, interbody spacers, and instrumentation for spinal surgeries. Additionally, Aurora Spine may engage in partnerships with healthcare providers and distributors to expand its market reach, which can further augment its sales and revenue. The company may also benefit from licensing agreements and collaborations with other medical technology firms, contributing to its overall earnings.

Aurora Spine Financial Statement Overview

Summary

Aurora Spine shows a mixed financial performance with revenue growth but persistent profitability challenges. The company faces issues with negative net income and cash flow generation, impacting its overall financial health. While leverage is moderate, the negative return on equity and cash flow constraints highlight areas needing improvement.

Income Statement

Aurora Spine's income statement shows a mixed performance. The company has achieved revenue growth, with a TTM (Trailing-Twelve-Months) revenue increase of 2.33%. However, profitability remains a concern, as indicated by negative net profit and EBIT margins. The gross profit margin is relatively healthy at 59.63%, but the negative net profit margin of -6.04% suggests challenges in controlling costs or achieving operational efficiency.

Balance Sheet

The balance sheet reflects moderate leverage with a debt-to-equity ratio of 0.89, which is manageable but has increased slightly over time. The return on equity is negative at -23.50%, indicating that the company is not generating profits from its equity base. The equity ratio stands at 34.14%, suggesting a reasonable level of equity financing, but the negative ROE highlights profitability issues.

Cash Flow

Cash flow analysis reveals challenges in generating free cash flow, with a negative growth rate of -22.70% in the TTM period. The operating cash flow to net income ratio is low at 0.20, indicating limited cash generation relative to net income. The free cash flow to net income ratio is 0.29, showing some ability to convert earnings into cash, but overall cash flow performance remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	18.38M	17.56M	14.52M	14.88M	10.54M	8.65M
Gross Profit	10.96M	10.63M	8.21M	7.81M	4.83M	3.47M
EBITDA	88.66K	179.90K	-446.20K	-469.27K	-1.90M	-573.86K
Net Income	-1.13M	-1.00M	-1.68M	-1.50M	-2.36M	-232.09K
Balance Sheet
Total Assets	11.57M	11.67M	11.99M	10.12M	10.56M	7.16M
Cash, Cash Equivalents and Short-Term Investments	580.98K	775.62K	766.83K	423.40K	3.17M	1.71M
Total Debt	3.63M	3.67M	3.65M	2.97M	2.38M	2.34M
Total Liabilities	7.62M	7.28M	6.69M	5.81M	4.99M	3.87M
Stockholders Equity	3.95M	4.40M	5.30M	4.32M	5.57M	3.28M
Cash Flow
Free Cash Flow	192.57K	266.47K	-1.41M	-2.43M	-2.85M	-245.07K
Operating Cash Flow	719.64K	904.33K	-935.06K	-1.56M	-2.13M	309.57K
Investing Cash Flow	-314.05K	-484.32K	-479.13K	-873.21K	-720.61K	-554.64K
Financing Cash Flow	-343.16K	-361.22K	1.76M	-318.15K	4.31M	1.51M

Aurora Spine Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.29
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ASG, the sentiment is Neutral. The current price of 0.29 is below the 20-day moving average (MA) of 0.30, above the 50-day MA of 0.29, and below the 200-day MA of 0.32, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.51 is Neutral, neither overbought nor oversold. The STOCH value of 37.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:ASG.

Aurora Spine Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRN	54 Neutral	C$251.54M	―	-106.37%	―	64.42%	-21.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
QIPT	49 Neutral	C$140.76M	-9.69	-9.96%	―	-0.70%	-102.48%
ASG	48 Neutral	C$23.03M	―	-26.27%	―	17.61%	-19.19%
PINK	46 Neutral	C$29.10M	-0.90	-233.44%	―	219.12%	-15.92%
TLT	45 Neutral	C$53.98M	-12.00	-291.69%	―	16.00%	9.79%
VPT	44 Neutral	C$16.77M	―	―	―	88.47%	11.88%

Aurora Spine Corporate Events

Aurora Spine Unveils Aurora Biologics to Enhance Spinal Fusion Success

Aurora Spine has launched Aurora Biologics, a new division aimed at enhancing spinal fusion success through innovative biologic solutions. This launch integrates seamlessly with Aurora’s existing spine ecosystem, offering a comprehensive platform that optimizes patient outcomes and surgical efficiency. The introduction of Aurora Biologics is expected to drive significant growth, with anticipated revenue increases and improved profit margins, positioning Aurora Spine as a leader in biologic performance in spine care.

The most recent analyst rating on (TSE:ASG) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Aurora Spine stock, see the TSE:ASG Stock Forecast page.

Aurora Spine Proposes Extension of Warrant Expiry Date

Aurora Spine Corporation has announced a proposed extension of the expiry date for 6,445,939 common share purchase warrants to October 15, 2026, pending approval from the TSX Venture Exchange. This move is part of the company’s strategic efforts to enhance its financial flexibility and potentially strengthen its market position in the spine and interventional pain management industry.

The most recent analyst rating on (TSE:ASG) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Aurora Spine stock, see the TSE:ASG Stock Forecast page.

Aurora Spine Launches Innovative Bone Density-Matched Lumbar Fusion Device

Aurora Spine has launched the DEXA-L™ Anterior Lumbar Interbody Fusion Device, a groundbreaking product in its DEXA™ Technology Platform. This device is the first of its kind, offering a bone density-matched implant for anterior lumbar interbody fusion procedures. It allows surgeons to tailor implants to match the bone density and quality of each patient, expanding treatment options for those with varying bone conditions, including osteopenia and osteoporosis. This advancement is expected to significantly impact the spinal surgery field by providing more personalized and effective treatment options.

The most recent analyst rating on (TSE:ASG) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Aurora Spine stock, see the TSE:ASG Stock Forecast page.

Aurora Spine Reports Record Q2 2025 Financial Results and Product Milestones

Aurora Spine Corporation reported a record second quarter for 2025, with revenues increasing by 10.2% to $4.5 million. The company achieved significant milestones, including surpassing 2,500 procedures using its SiLO SI Joint Fusion System and 1,500 surgeries with DEXA-C. Aurora is preparing to launch its new FDA-cleared Hydra A.E.R.O. product and has seen a 70% increase in cervical sales, primarily due to the DEXA-C implant. The company is also focusing on improving its presence in the lumbar spine field with the upcoming launch of the DEXA-L series. Management highlighted the company’s strong operational performance and continued efforts to educate the marketplace about its minimally invasive procedures.

The most recent analyst rating on (TSE:ASG) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Aurora Spine stock, see the TSE:ASG Stock Forecast page.